Cellbyte Raises $2.75M Funding In Seed Round

The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels.

The funding will fuel Cellbyte’s international expansion, triple its team, and further automate drug launch workflows. Within weeks of launch, the company reached six-figure ARR and secured contracts with major pharmaceutical firms, including Bayer.

Read Also - Voltrac Raises €7M To scale Its Autonomous Electric Tractor Targeting Agricultural Labour Shortages

Felix Steinbrenner, Co-CEO and Co-Founder at Cellbyte said: “The success of a drug’s entire lifecycle is decided in its launch sequence. Insights derived from gigabytes of accurate, up-to-date information are needed to make the best decisions for a launch.

“The traction Cellbyte has secured with some of the world’s biggest pharmaceutical companies since its launch shows the industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes.”

Cellbyte’s platform empowers Market Access teams to analyze millions of data points in real time across clinical, pricing, HTA and regulatory information. By replacing outdated databases that provide limited insights, it enables users to generate reports and actionable insights in minutes instead of months.

Daniel Moreira, Co-CEO and Co-Founder at Cellbyte said: “Based on my years in Life Science Consulting, I’ve seen countless innovations transforming clinical development. Yet in Pricing and Market Access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now, generative AI is changing that, and we’re proud to be driving this shift.”

William McQuillan, Partner at Frontline Ventures said: “Cellbyte is tackling one of pharma’s biggest bottlenecks with an AI-driven strategy. Felix, Samuel and Daniel have set their sights globally from day one, and we’re proud to support them as they expand into the US, accelerating patient access to new treatments.”

About Cellbyte

Founded in 2024 Cellbyte is an AI-native platform that accelerates global drug launches for pharmaceutical companies. By automating pricing, market access and regulatory workflows it turns complex data into actionable insights, enabling faster decisions.